Researchers at the University of Gothenburg have identified a protein linked to an increased risk of metastasis and recurrence in lung cancer. The findings are presented in a study that paves the way ...
New research published in Nature finds that tumor cells within supratentorial ependymomas (SE) – an aggressive childhood brain cancer – cluster into distinct tumor cell populations. Much like a ...
Women with de novo metastatic breast cancer that is confined to a single distant organ may live longer when they undergo resection of the primary tumor, a large cohort study suggested. The study, of ...
Lifileucel (Amtagvi) is an approved tumor-infiltrating lymphocyte (TIL) therapy for patients with advanced melanoma, but there are limited data on treatment of patients with brain ...
An enigmatic type of circulating tumor cell called a dual-positive (DP) cell is associated with shorter survival time in patients with advanced breast cancer, according to a study led by investigators ...
Radiopharm Theranostics maintains a "Hold" rating as its radiotherapeutic pipeline advances, with key data readouts expected in 2026. Click here to read.
News-Medical.Net on MSN
Dual-positive hybrid cells linked to shorter survival in advanced breast cancer
An enigmatic type of circulating tumor cell called a dual-positive (DP) cell is associated with shorter survival time in patients with advanced breast cancer, according to a study led by investigators ...
MYC amplification is associated with reduced tumor immunogenicity as assessed by the recovery of IR recombination reads from prostate cancer genomics ...
Pancreatic cancer is one of the most aggressive and deadly forms of cancer. It is often diagnosed at a late stage, when the disease has already spread to other organs such as the liver. Because of ...
Ipsen is withdrawing tazemetostat from all markets following signals of secondary hematologic malignancies observed in SYMPHONY-1 evaluating tazemetostat plus lenalidomide/rituximab versus ...
At the 2026 Miami Breast Cancer Conference, Kevin Kalinsky, MD, MS, participated in a molecular tumor board session that brought together a multidisciplinary panel including medic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results